-+ 0.00%
-+ 0.00%
-+ 0.00%

VolitionRx To Highlight Use Of Its Nu.Q Cancer Assays In Management Of Lung Cancer Patients At European Lung Cancer Conference

Benzinga·03/26/2026 12:20:13
Listen to the news

VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, announces the presentation of an abstract at the European Lung Cancer Conference (ELCC) in Copenhagen, Denmark this week. The poster highlighted the use of its Nu.Q® Cancer assays in the management of lung cancer patients.